My Companies
Notification
Account
Natco Pharma said the USFDA inspected its Kothur, Hyderabad manufacturing facility from November 12 to 20, 2026 and issued seven Form-483 observations, which the company described as procedural and said it would address comprehensively within stipulated timelines.
Natco Pharma Sets ₹1,279 Crore Rights Issue At ₹750 Per Share
Natco Pharma Fixes ₹750 Price For ₹1,279 Crore 2:21 Rights Issue
Natco Pharma Proposes ₹1,300 Crore Rights Issue For Debt Repayment
Natco Pharma Approves Rights Issue Of Up To ₹1,300 Crore
Natco Pharma Explores ₹2,000 Crore Capital Raise Alongside Q1 Results